Examining the implications of the recent US executive orders concerning diversity, equity, and inclusion pursuits—and the key questions each clinical trial stakeholder must now navigate.

In this video interview, Thierry Escudier, portfolio lead, Pistoia Alliance, highlights the need for maintaining data privacy in a highly regulated clinical research industry.

These were across five common KRIs (adverse events, serious adverse events, screen failure, early termination, and data entry ...

Exploring the different stages in the development of a digital measure, and the activities and steps key to achieving ...

As oncology research centers scale eSource adoption, the field is shifting toward a fully digital, clinical trial ecosystem.

Since the Orphan Drug Act went into effect in 1983, more than 600 drugs have been approved for rare diseases, according to ...

The future of clinical trial design involves incorporating the patient experience into strategic asset planning.

Why investing in truly effective training from the outset can pay off exponentially for clinical teams—and serve as a ...

Many clinical researchers lament the rise of misinformation and yearn for the orderly days of fewer, more authoritative ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage ...

Research collaboration between Tufts and the Society for Clinical Research Sites explores the prevalence of this belief in ...

In this video interview, Thierry Escudier, portfolio lead, Pistoia Alliance, discusses the alliance’s latest step in ...